Business Description
Apellis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03753U1060
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.76 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.8 | |||||
Debt-to-EBITDA | -1.59 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.84 | |||||
Beneish M-Score | 11.12 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.1 | |||||
3-Year EBITDA Growth Rate | -0.2 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | -31.5 | |||||
3-Year Book Growth Rate | -15.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 50.62 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.75 | |||||
9-Day RSI | 43.89 | |||||
14-Day RSI | 37.58 | |||||
6-1 Month Momentum % | -27.7 | |||||
12-1 Month Momentum % | -27.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.08 | |||||
Quick Ratio | 4.18 | |||||
Cash Ratio | 2.13 | |||||
Days Inventory | 564.5 | |||||
Days Sales Outstanding | 122.93 | |||||
Days Payable | 126.4 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.2 | |||||
Shareholder Yield % | -2.61 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.38 | |||||
Operating Margin % | -49.8 | |||||
Net Margin % | -52.94 | |||||
FCF Margin % | -65.11 | |||||
ROE % | -127.72 | |||||
ROA % | -39.08 | |||||
ROIC % | -107.81 | |||||
ROC (Joel Greenblatt) % | -136.33 | |||||
ROCE % | -45.91 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 451.4 | |||||
PS Ratio | 5.45 | |||||
PB Ratio | 12.89 | |||||
Price-to-Tangible-Book | 12.89 | |||||
EV-to-EBIT | -11.75 | |||||
EV-to-Forward-EBIT | 65.2 | |||||
EV-to-EBITDA | -11.81 | |||||
EV-to-Forward-EBITDA | 61.67 | |||||
EV-to-Revenue | 5.6 | |||||
EV-to-Forward-Revenue | 3.51 | |||||
EV-to-FCF | -8.62 | |||||
Price-to-Net-Current-Asset-Value | 15.47 | |||||
Earnings Yield (Greenblatt) % | -8.51 | |||||
FCF Yield % | -11.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Apellis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 581.718 | ||
EPS (TTM) (€) | -2.541 | ||
Beta | 0 | ||
Volatility % | 50.75 | ||
14-Day RSI | 37.58 | ||
14-Day ATR (€) | 0.679608 | ||
20-Day SMA (€) | 25.70175 | ||
12-1 Month Momentum % | -27.65 | ||
52-Week Range (€) | 24.145 - 65.5 | ||
Shares Outstanding (Mil) | 121.77 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Apellis Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Apellis Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Apellis Pharmaceuticals Inc Frequently Asked Questions
What is Apellis Pharmaceuticals Inc(STU:1JK)'s stock price today?
When is next earnings date of Apellis Pharmaceuticals Inc(STU:1JK)?
Does Apellis Pharmaceuticals Inc(STU:1JK) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |